Immunovia (IMMV.F) Stock Overview

A diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. More details

IMMV.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 81.97% per year

Earnings have grown 8.2% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (SEK1M)

Shares are highly illiquid

+ 2 more risks

IMMV.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW436,082 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

436,082 investors already sharing narratives

View all narratives

Immunovia AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Immunovia
Historical stock prices
Current Share Price	SEK 0.01
52 Week High	SEK 0.02
52 Week Low	SEK 0.01
Beta	2.64
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Shareholder Returns

	IMMV.F	US Medical Equipment	US Market
7D	0%	-5.1%	-0.2%
1Y	n/a	-17.5%	14.8%

Return vs Industry: Insufficient data to determine how IMMV.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how IMMV.F performed against the US Market.

Price Volatility

Is IMMV.F's price volatile compared to industry and market?
IMMV.F volatility
IMMV.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.4%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stable Share Price: IMMV.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IMMV.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	18	Jeff Borcherding	www.immunovia.com

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Immunovia AB (publ) Fundamentals Summary

How do Immunovia's earnings and revenue compare to its market cap?
IMMV.F fundamental statistics
Market cap	US$10.52m
Earnings (TTM)	-US$9.21m
Revenue (TTM)	US$126.23k

83.3x

P/S Ratio

-1.1x

P/E Ratio

Is IMMV.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMV.F income statement (TTM)
Revenue	SEK 1.21m
Cost of Revenue	SEK 521.00k
Gross Profit	SEK 690.00k
Other Expenses	SEK 89.03m
Earnings	-SEK 88.33m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Nov 05, 2026

Earnings per share (EPS)	-0.13
Gross Margin	56.98%
Net Profit Margin	-7,294.38%
Debt/Equity Ratio	0%

How did IMMV.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/09 15:29
End of Day Share Price	2026/09/02 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovia AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Niklas Elmhammer	Carlsquare AB
Herman Kuntscher	Carlsquare AB
Lars Hevreng	Danske Bank

Immunovia (IMMV.F) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Immunovia AB (publ) Competitors

Sintx Technologies

Scientific Industries

Biomerica

ENDRA Life Sciences

Price History & Performance

Recent News & Updates

Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage

Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure

Immunovia AB Receives State Regulatory Approval for Pancreasure in California and Initiates Commercial Rollout

Immunovia AB (publ), Annual General Meeting, May 15, 2026

Immunovia AB (publ) to Report Q3, 2026 Results on Nov 05, 2026

Immunovia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100 million.

Recent updates

Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage

Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure

Immunovia AB Receives State Regulatory Approval for Pancreasure in California and Initiates Commercial Rollout

Immunovia AB (publ), Annual General Meeting, May 15, 2026

Immunovia AB (publ) to Report Q3, 2026 Results on Nov 05, 2026

Immunovia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100 million.

Immunovia AB (publ) Approves Board Changes

Immunovia Provides Further Positive Data from the Verifi Study of Its Next-Generation Pancreatic Cancer Test

Immunovia Announces Another Successful Clinical Validation of Its Next-Generation Pancreatic Cancer Test

Immunovia AB (Publ) Announces Karin Almqvist Liwendahl Step Down as CFO

Immunovia AB (Publ) Appoints Nomination Committee

Immunovia AB (publ), Annual General Meeting, May 14, 2025

Immunovia AB (publ) to Report Q3, 2025 Results on Nov 19, 2025

Immunovia AB (publ) Announces Positive Outcome and Strong Accuracy in the Clinical Validation of Its Next-Generation Test for Pancreatic Cancer

Immunovia Presents Model-Development Study Results At Meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers

Immunovia AB (Publ) Acquires All Blood Samples Required to Clinically Validate Its Next-Generation Test for Pancreatic Cancer

Immunovia Completes Analytical Validation of Its Next-Generation Pancreatic Cancer Test

Immunovia AB (publ) Announces the Next-Generation Test to Be Included in Large Study of Pancreatic Cysts funded by the U.S. National Institutes of Health

Immunovia Files US Patent Application to Protect Its Next-Generation Test

Immunovia Completes Development of Its Pancreatic Cancer Detection Test After Substantially Increasing Test Accuracy

Immunovia AB Presents Detailed Discovery Study Results for its Next-Generation Early Detection Test for Pancreatic Cancer at PancreasFest 2024 Annual Meeting

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023